Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Upgrades 2025 full-year CDMO sales and margin outlook
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Subscribe To Our Newsletter & Stay Updated
